morbillivirus
form
separ
genu
within
paramyxovirina
subfamili
paramyxovirida
famili
order
mononegaviral
current
six
virus
classifi
within
morbilliviru
genu
rinderpest
viru
rpv
measl
viru
mev
canin
distemp
viru
cdv
pest
de
petit
rumin
pprv
phocin
distemp
viru
pdv
cetacean
morbilliviru
cemv
recent
rinderpest
consid
archetyp
morbilliviru
predict
exist
year
howev
propos
rinderpest
measl
diverg
ancestr
viru
recent
time
centuri
mev
caus
million
human
death
annual
vaccin
becam
avail
earli
cdv
affect
mani
terrestri
marin
carnivor
pprv
infect
small
rumin
larg
rumin
deadli
infect
rinderpest
larg
bovid
two
morbillivirus
phocin
distemp
viru
pdv
affect
seal
pinnip
cetacean
morbilliviru
cemv
threaten
dolphin
porpois
also
caus
mass
dieoff
marin
speci
virus
within
order
mononegaviral
contain
negativesens
singlestrand
rna
genom
consist
six
open
read
frame
encod
six
structur
two
nonstructur
protein
nucleocapsid
n
phosphoprotein
p
larg
polymeras
protein
l
tandem
viral
rna
form
ribonucleoprotein
complex
rnp
matrix
protein
form
link
rnp
host
cell
deriv
plasma
membran
cover
evenli
distinct
spike
viral
glycoprotein
haemagglutinin
h
fusion
protein
f
interact
h
f
protein
govern
viru
entri
host
cell
review
exist
vaccin
morbillivirus
discuss
idea
futur
vaccin
develop
potenti
erad
earli
experi
rinderpest
viru
rpv
shift
focu
anim
diseas
manag
alter
direct
veterinari
scienc
import
ramif
medic
scienc
inde
repeat
attempt
cure
rinderpest
viru
led
observ
serum
obtain
recov
individu
protect
administ
anim
subsequ
expos
alter
scientif
emphasi
treatment
prevent
herald
new
dawn
vaccinolog
inocul
viru
immun
serum
convalesc
anim
prepar
hyperimmun
serum
goat
progress
applic
immun
serum
given
either
alon
combin
infect
blood
robert
koch
demonstr
combin
immun
serum
virul
blood
induc
activ
immun
approach
term
serumviru
simultan
method
appli
wide
across
africa
india
protect
livestock
rinderpest
whilst
highli
effect
method
suffer
drawback
includ
induct
diseas
young
immunosuppress
anim
includ
pregnant
anim
infecti
natur
vaccine
instabl
prepar
potenti
transmiss
piroplasm
present
within
inocul
prepar
next
stage
vaccin
gener
rpv
involv
develop
inactiv
rpv
vaccin
earli
inactiv
vaccin
prepar
produc
infect
bovin
tissu
chemic
inactiv
field
applic
inactiv
rpv
vaccin
success
clear
rpv
sever
countri
includ
iran
philippin
sri
lanka
thailand
russia
howev
immun
produc
inactiv
vaccin
short
live
live
attenu
vaccin
strain
develop
follow
multipl
passag
differ
host
first
produc
goat
cheap
efficaci
transmit
piroplasm
one
kabet
attenu
goat
kag
vaccin
shown
induc
long
live
neutralis
antibodi
respons
rpv
lapin
version
rpv
vaccin
develop
korea
japan
due
shortag
goat
found
better
suit
asiat
breed
cattl
limit
number
dose
produc
singl
rabbit
led
passag
goat
sheep
final
product
use
erad
rpv
china
japan
korea
vaccin
also
gener
ovo
overcom
advers
reaction
seen
lapin
vaccin
highli
suscept
cattl
develop
attenu
vaccin
differ
host
speci
reduc
labour
requir
mass
product
vaccin
develop
tissu
cultur
base
vaccin
mass
product
econom
viabl
cost
could
achiev
earli
attempt
passag
attenu
virus
tissu
cultur
hamper
lack
suscept
cell
line
viru
cultur
attempt
use
adapt
strain
rinderpest
chicken
embryo
fibroblast
cef
bovin
kidney
bk
cell
bovin
embryon
kidney
cell
unsuccess
late
virul
strain
rpv
success
attenu
primari
calf
kidney
cultur
initi
passag
result
increas
virul
follow
passag
virul
reduc
viru
deem
complet
attenu
unabl
caus
diseas
even
suscept
breed
cattl
vaccin
term
tissu
cultur
rinderpest
vaccin
tcrv
abl
elicit
long
term
neutralis
antibodi
respons
protect
challeng
sever
year
postvaccin
without
caus
advers
reaction
tcrv
use
extens
across
develop
world
vaccin
cattl
rpv
prove
highli
effect
tool
erad
rinderpest
howev
one
drawback
relat
tcrv
serolog
signatur
vaccin
anim
ident
develop
anim
infect
natur
field
surviv
infect
sinc
one
serotyp
rpv
meant
oie
gold
standard
competit
elisa
base
antih
monoclon
antibodi
unabl
fulfil
diva
requir
abil
differenti
serolog
signatur
natur
infect
vaccin
anim
global
rinderpest
erad
programm
success
sever
candid
diva
vaccin
develop
may
found
util
recombin
rpv
vaccin
express
foreign
gene
gfp
ha
develop
although
serolog
respons
foreign
gene
suffici
develop
recombin
rpv
rpv
n
protein
swap
close
relat
pprv
cattl
vaccin
recombin
vaccin
protect
rpv
challeng
companion
elisa
test
develop
accompani
vaccin
enabl
diva
although
success
erad
rpv
preclud
use
altern
approach
show
promis
vaccin
develop
morbillivirus
gener
neg
mark
vaccin
epitop
delet
novel
diva
initi
may
find
util
develop
diva
vaccin
morbillivirus
success
global
erad
smallpox
announc
incent
oie
fao
examin
feasibl
set
goal
rinderpest
year
sever
factor
relat
virul
patholog
epidemiolog
rinderpest
recognis
favour
global
rinderpest
erad
plan
grep
includ
limit
geograph
distribut
diseas
latenc
persist
viru
infect
anim
short
infecti
period
requir
direct
close
indirect
contact
transmiss
viru
avail
tcrv
highli
sensit
specif
companion
diagnost
test
crucial
erad
campaign
econom
signific
larg
rumin
across
develop
world
gave
polit
econom
impetu
drive
erad
campaign
complet
final
year
long
campaign
launch
oie
announc
rpv
second
pathogen
success
erad
world
human
effort
develop
vaccin
measl
facilit
isol
viru
human
monkey
renal
cell
expos
whole
blood
throat
wash
obtain
patient
infect
measl
cultiv
isol
viral
materi
chick
embryo
fibroblast
cef
led
gener
first
attenu
measl
vaccin
edmonstonb
strain
licens
use
although
vaccin
effect
prevent
measl
infect
administ
human
gamma
globulin
commonli
caus
advers
reaction
vaccine
includ
fever
rash
attempt
amelior
side
effect
studi
carri
develop
inactiv
viru
vaccin
new
formul
offer
protect
diseas
also
caus
atyp
form
measl
patient
expos
wildtyp
viru
postvaccin
mauric
hilleman
propag
edmonstonb
vaccin
strain
forti
passag
cef
cell
increas
attenu
viru
result
gener
moraten
strain
attenu
ender
new
live
attenu
version
caus
side
effect
accompani
ender
vaccin
equal
effect
licens
human
vaccin
stoke
et
al
publish
result
studi
trival
vaccin
measl
mump
rubella
virus
vaccin
known
mmr
cocktail
three
live
attenu
virus
shown
protect
vaccin
individu
measl
mump
rubella
respect
sinc
licens
use
vaccin
million
peopl
countri
across
world
origin
administ
onedos
vaccin
second
dose
introduc
produc
immun
high
enough
disrupt
measl
transmiss
vaccin
popul
link
mmr
vaccin
occurr
autism
bowel
diseas
made
wakefield
et
al
base
studi
involv
twelv
children
public
spark
last
controversi
despit
fact
subsequ
report
extens
discredit
initi
data
although
wakefield
public
fulli
retract
ethic
methodolog
ground
articl
public
concern
caus
accompani
press
coverag
profound
effect
uptak
mmr
vaccin
studi
vaccin
uptak
uk
reveal
consciou
parent
choic
reason
parent
refus
vaccin
children
mmr
safeti
concern
part
legaci
origin
public
signific
impact
reemerg
measl
viru
popul
across
europ
previous
absent
follow
drop
immun
afford
vaccin
coverag
drop
level
requir
prevent
viru
spread
within
commun
fig
uk
mmr
controversi
origin
start
measl
vaccin
coverag
also
drop
consequ
signific
increas
diseas
case
observ
april
june
children
receiv
first
dose
mmr
year
age
compar
period
import
vaccin
shown
studi
summaris
measl
incid
five
european
countri
major
case
unvaccin
incomplet
vaccin
children
despit
public
concern
mmr
regard
scientif
commun
one
safest
vaccin
avail
moreov
measl
viru
possess
sever
featur
make
ideal
candid
recombin
vaccin
develop
develop
revers
genet
techniqu
made
manipul
subsequ
gener
recombin
live
virus
possibl
tool
extens
utilis
morbillivirus
contrari
might
expect
rna
viru
mev
recombin
genet
stabl
shown
revert
back
virul
phenotyp
risk
accumul
mutat
neutralis
epitop
order
escap
protect
immun
respons
confer
vaccin
strain
could
theoret
expect
despit
high
degre
mutat
rna
virus
event
ever
observ
measl
also
morbillivirus
rpv
pprv
asset
along
capabl
accept
kb
foreign
sequenc
induct
humor
cellular
immun
respons
good
safeti
record
vaccin
strain
low
product
cost
made
mev
vector
choic
develop
vaccin
numer
foreign
pathogen
recombin
oncolyt
virus
date
surfac
protein
sever
heterolog
virus
express
mev
backbon
immunogen
foreign
protein
examin
suscept
host
tabl
refer
therein
success
global
elimin
rinderpest
viru
highlight
feasibl
measl
erad
sever
factor
relat
biolog
viru
characterist
current
vaccin
favour
erad
idea
measl
viru
like
morbillivirus
antigen
monotyp
mean
seroconvers
recoveri
diseas
success
vaccin
protect
strain
viru
known
anim
reservoir
viru
infect
suscept
nonhuman
primat
consid
dead
end
host
due
insuffici
popul
size
therefor
risk
spill
event
unlik
hamper
control
effort
mev
licens
vaccin
safe
administ
immunocompromis
individu
safe
two
dose
vaccin
administ
around
month
year
age
abl
induc
protect
least
sever
decad
life
time
exist
diagnost
assay
great
util
although
pointofcar
test
would
improv
diagnost
potenti
similar
develop
rumin
morbillivirus
limit
mev
vaccin
howev
exist
includ
potenti
interfer
matern
antibodi
young
children
prevent
strong
protect
respons
factor
led
reemerg
mev
highli
vaccin
popul
effort
overcom
poor
paediatr
vaccin
efficaci
use
high
titr
vaccin
attempt
stop
mortal
report
dna
vaccin
propos
altern
vaccin
linig
et
al
singl
multipl
antigen
simian
immunodefici
viru
siv
induct
strong
humor
respons
vaccin
anim
zuniga
et
al
strategi
infant
vivo
studi
demonstr
potenti
util
altern
viral
vector
deliveri
mev
glycoprotein
also
assess
diseas
clinic
manifest
match
canin
distemp
report
centuri
plagu
anim
across
globe
canin
distemp
viru
cdv
initi
thought
restrict
infect
member
canida
although
last
year
caus
outbreak
wide
varieti
host
includ
member
felida
hyaenida
mustelida
procyonida
ursida
viverrida
ailurida
mephitida
alongsid
cdv
implic
caus
extens
distemp
outbreak
seal
popul
dog
cdv
gener
associ
pessimist
prognosi
dramat
impact
wildlif
speci
increas
awar
diseas
outbreak
cdv
kill
sever
tiger
lion
leopard
kept
american
zoo
unexpect
event
sinc
cdv
previous
thought
caus
clinic
diseas
felid
two
year
later
larg
outbreak
decim
popul
lion
serengeti
nation
park
tanzania
reduc
popul
estim
outbreak
sever
hyena
cub
also
fell
victim
cdv
tanzania
recent
outbreak
among
african
wild
dog
lycaon
pictu
kill
breed
anim
month
fact
distemp
outbreak
domest
wildlif
speci
regularli
report
across
world
moreov
recent
viru
expand
host
rang
nonhuman
primat
name
rhesu
monkey
macaca
mulatta
china
cynomolgu
monkey
macaca
fasciculari
japan
report
highlight
need
cdv
vaccin
use
control
diseas
domest
wild
anim
recent
modifi
live
vaccin
mlv
cdv
introduc
earli
avail
first
onderstepoort
vaccin
develop
natur
isol
passag
ferret
adapt
chicken
embryo
later
replac
chicken
cell
cultur
gener
adapt
rockborn
strain
canin
kidney
cell
cultur
canin
adapt
cell
cultur
vaccin
offer
protect
almost
vaccin
dog
rare
occas
caus
postvaccin
enceph
two
vaccin
significantli
reduc
cdv
infect
domest
dog
popul
although
vaccin
found
insuffici
attenu
use
wildlif
speci
exampl
cdv
vaccin
gener
canin
cell
caus
diseas
grey
fox
urocyon
cinereoargenteu
ferret
mustela
nigrip
avian
attenu
vaccin
fatal
european
mink
mustela
lutreola
ferret
gener
avian
cell
adapt
vaccin
consid
safer
wildlif
speci
toler
grey
red
fox
vulp
vulp
bush
dog
speotho
venaticu
mane
wolv
chrysocyon
brachyuru
fennec
fox
vulp
zerda
contrast
mention
speci
canin
cell
adapt
vaccin
found
safe
red
fox
problem
associ
mlv
vaccin
especi
unsuit
mani
endang
speci
incent
develop
recombin
vaccin
could
safe
use
speci
recent
gener
recombin
cdv
vaccin
incorpor
fusion
f
haemagglutinin
h
protein
cdv
strain
canarypox
viru
shown
safe
suscept
speci
test
date
includ
dog
european
ferret
mustela
putoriu
furo
giant
panda
ailuropoda
melanoleuca
fennec
fox
meerkat
suricata
suricatta
siberian
polecat
mustela
eversmanni
whilst
canarypox
vector
vaccin
safe
numer
target
speci
replic
incompet
induc
milder
immunolog
respons
mlv
vaccin
howev
latter
featur
highlight
applic
immunis
young
anim
presenc
matern
antibodi
attempt
employ
revers
genet
techniqu
studi
develop
novel
vaccin
concept
ration
attenu
cdv
modifi
viral
rna
polymeras
l
protein
express
report
gene
within
open
read
frame
led
viral
attenu
previous
demonstr
morbillivirus
similarli
deplet
cdv
h
protein
nlink
glycosyl
site
produc
viru
attenu
phenotyp
longer
abl
caus
diseas
ferret
approach
centr
around
gener
chimer
viru
combin
replic
complex
mev
moraten
strain
glycoprotein
wildtyp
cdv
result
recombin
caus
clinic
sign
immunosuppress
vaccin
anim
induc
protect
immun
lethal
challeng
dna
vaccin
formul
similar
way
describ
mev
also
shown
promis
induc
strong
protect
humor
cellmedi
immun
respons
although
effect
rel
inexpens
produc
problem
associ
vaccin
regim
deliveri
rout
must
resolv
make
dna
vaccin
effect
altern
mlv
wildlif
popul
final
cdv
recent
use
vector
express
rabi
viru
glycoprotein
chimer
viru
induc
strong
rabi
neutralis
antibodi
respons
protect
mice
lethal
dose
rabi
viru
shown
safe
mice
dog
although
cdv
challeng
experi
carri
vaccin
result
product
longlast
neutralis
antibodi
cdv
rabi
demonstr
potenti
multival
morbilliviru
vaccin
pest
de
petit
rumin
ppr
first
identifi
diseas
small
rumin
distinct
rpv
classifi
fourth
member
morbilliviru
genu
alongsid
rpv
mev
cdv
ppr
endem
across
larg
part
africa
asia
mani
year
tcrv
use
effect
protect
sheep
goat
pprv
crossneutralis
antibodi
respons
afford
protect
least
month
howev
need
stop
vaccin
anim
tcrv
rinderpest
erad
meant
homolog
pprv
vaccin
nigeria
requir
vaccin
gener
serial
passag
virul
pprv
strain
cell
cultur
report
abl
protect
goat
sheep
challeng
wildtyp
pprv
isol
least
year
postvaccin
exist
one
serotyp
pprv
mean
vaccin
protect
challeng
virus
four
pprv
lineag
current
sever
pprv
vaccin
licens
alongsid
nigeria
vaccin
live
attenu
vaccin
use
india
wide
accept
rpv
erad
diva
vaccin
would
great
util
combat
pprv
howev
develop
vaccin
hamper
lack
revers
genet
system
pprv
hurdl
overcom
murali
et
al
hu
et
al
report
develop
recombin
form
pprv
altern
rpv
erad
tcrv
base
recombin
could
use
diva
purpos
develop
da
et
al
gener
chimer
rpv
contain
glycoprotein
pprv
recombin
vaccin
protect
anim
virul
challeng
fulfil
diva
principl
reluct
utilis
vaccin
viru
base
rpv
posterad
era
mean
diva
tool
unlik
use
research
group
propos
differ
approach
design
diva
vaccin
engin
capripox
viru
express
pprv
h
protein
use
field
serolog
profil
anim
vaccin
recombin
vaccin
could
distinguish
natur
infect
anim
absenc
antibodi
direct
viral
protein
includ
vaccin
formul
although
initi
trial
show
capripox
vaccin
protect
goat
challeng
virul
strain
pprv
field
studi
carri
given
similar
rpv
pprv
believ
futur
plan
pprv
elimin
requir
implement
principl
led
rinderpest
erad
howev
requir
met
coordin
action
pprv
initi
importantli
knowledg
epidemiolog
pprv
wildlif
improv
rpv
regularli
report
wildlif
speci
gener
accept
wildlif
popul
victim
viru
circul
domest
cattl
rather
reservoir
infect
role
wildlif
transmiss
ppr
remain
elucid
although
sever
speci
report
suscept
addit
gap
understand
pprv
epidemiolog
financi
cost
possibl
erad
campaign
also
unknown
may
difficult
estim
shorter
lifespan
small
rumin
compar
cattl
mean
turnov
rate
higher
turn
result
need
vaccin
train
veterinari
servic
carri
vaccin
administr
factor
need
address
formul
viabl
erad
programm
success
elimin
rpv
highlight
potenti
erad
morbillivirus
initi
erad
mev
underway
coordin
despit
mev
still
caus
death
thousand
children
africa
due
controversi
associ
mmr
vaccin
even
develop
countri
experienc
extens
epidem
regular
vaccin
help
reduc
cdv
incid
dog
viru
caus
mass
dieoff
wildlif
speci
alreadi
verg
extinct
addit
new
morbilliviru
name
felin
morbilliviru
fmopv
recent
discov
domest
cat
feli
catu
battl
morbillivirus
continu
develop
vaccin
particular
diva
vaccin
aid
abil
disrupt
circul
virus
potenti
aid
erad
morbillivirus
wake
success
rpv
erad
